Relevant bibliographies by topics / Suspension nasal spray

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Conference papers

Academic literature on the topic 'Suspension nasal spray'

Author: Grafiati
Published: 4 June 2021
Last updated: 17 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Suspension nasal spray.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Suspension nasal spray"

1

MCNAMARA, DAMIAN. "Omnaris Nasal Spray, Allegra Oral Suspension." Pediatric News 40, no. 12 (December 2006): 54. http://dx.doi.org/10.1016/s0031-398x(06)71572-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

MCNAMARA, DAMIAN. "Patanase Nasal Spray, Prilosec Delayed- Release Oral Suspension." Pediatric News 42, no. 5 (May 2008): 31. http://dx.doi.org/10.1016/s0031-398x(08)70230-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Chudiwal, Swapnil Sharadkumar, and Mohamed Hassan G. Dehghan. "Quality by design approach for development of suspension nasal spray products: a case study on budesonide nasal suspension." Drug Development and Industrial Pharmacy 42, no. 10 (March 27, 2016): 1643–52. http://dx.doi.org/10.3109/03639045.2016.1160108.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Shah, Samir A., Robert L. Berger, John McDermott, Pranav Gupta, David Monteith, Alyson Connor, and Wu Lin. "Regional deposition of mometasone furoate nasal spray suspension in humans." Allergy and Asthma Proceedings 36, no. 1 (January 21, 2015): 48–57. http://dx.doi.org/10.2500/aap.2015.36.3817.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mahmud, Khaled, MN Faruque, and KA Faisal. "The Effect of Preoperative Short Course of Oral Steroids followed by Postoperative Topical Nasal Steroids Sprays on Nasal Polyp Recurrence after Endoscopic Nasal Polypectomy." Journal of Dhaka National Medical College & Hospital 17, no. 2 (October 17, 2012): 40–43. http://dx.doi.org/10.3329/jdnmch.v17i2.12215.

Full text
Abstract:
Objective: To evaluate the effect of preoperative short course of oral steroids followed by postoperative topical nasal steroids sprays on nasal polyp recurrence after endoscopic nasal polypectomy. Methods: Forty eight patients of both genders with symptoms and signs of nasal polyps were included in this prospective study between January 2006 and December 2009. Their ages ranged between 18 and 60 years. The sample was divided into two groups. Group I constituted 24 patients treated by endoscopic nasal polypectomy without oral and local steroid therapy. Group II consisted of 24 patients also treated by endoscopic nasal polypectomy but received preoperatively 60mg prednisolone tablets daily for one week and postoperatively topical nasal steroid spray (Mometasone furoate suspension) for three months. All patients were followed up for at least one year. Recurrence of nasal polyps was assessed endoscopically at three, six and 12 months after surgery. Any evidence of nasal polyps-formation of whatever size was considered as recurrence. Results: Forty eight patients (32 males and 16 females) with sinonasal polyposis were included in this study. Male to female ratio was 2:1. Patients’ age ranged from 18 to 60 years; median age was 42 years. Recurrence rates at three, six and 12 months after surgery for the first group of patients were 8.33% (2 patients), 25% (6 patients) and 41.6% (10 patients) accordingly, while the recurrence rates for the second group were 4.1% (1 patient), 8.3% (2 patients) and 12.5% (3 patients) accordingly. Conclusions: Preoperative short course of oral steroid followed by postoperative nasal steroid spray show significant reduction in the recurrence rate of nasal polyps after endoscopic nasal polypectomy. DOI: http://dx.doi.org/10.3329/jdnmch.v17i2.12215 J. Dhaka National Med. Coll. Hos. 2011; 17 (02): 40-43
APA, Harvard, Vancouver, ISO, and other styles
6

Ricchetti, Alma, Basile N. Landis, Alessandra Maffioli, Roland Giger, Chungkuan Zeng, and Jean-Silvain Lacroix. "Effect of anti-fungal nasal lavage with amphotericin B on nasal polyposis." Journal of Laryngology & Otology 116, no. 4 (April 2002): 261–63. http://dx.doi.org/10.1258/0022215021910708.

Full text
Abstract:
Recent studies have suggested that allergic fungal rhino-sinusitis could be involved in the development of nasal polyposis. The aim of this study was to evaluate the response of anti-fungal nasal lavages. Patients performed nasal lavage with 20 ml of a one per one thousand amphotericin B suspension in each nostril, twice a day, for four weeks. In addition, all patients continued their saline nasal lavage and their conventional topical corticosteroid spray. This study included 74 patients, with a mean age of 46 years (range from 19 to 73). Before anti-fungal treatment, the distribution of nasal polyposis, according to Malm, was: 13 patients in stage I (17.5 per cent), 48 patients in stage II (65 per cent) and 13 patients in stage III (17.5 per cent). After anti-fungal nasal lavages, the total disappearance of nasal polyposis was observed in 29 patients (39 per cent). Eight patients were stage I, 21 stage II, and none stage III. In patients who have had previous endoscopic polypectomy and functional endoscopic sinus surgery, total disappearance of nasal polyposis was seen in 24 patients (47 per cent). Hyper-reactivity to fungal organisms could be one of the mechanisms underlying the development of nasal polyposis. A direct effect of amphotericin B suspension on the integrity of the cell membrane of the polyps’ epithelium could not be excluded.
APA, Harvard, Vancouver, ISO, and other styles
7

Pennington, Justin, Preetanshu Pandey, Henry Tat, Jennifer Willson, and Brent Donovan. "Spray Pattern and Droplet Size Analyses for High-Shear Viscosity Determination of Aqueous Suspension Corticosteroid Nasal Sprays." Drug Development and Industrial Pharmacy 34, no. 9 (January 2008): 923–29. http://dx.doi.org/10.1080/03639040802149046.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Day, James, Michael Alexander, Michel Drouin, Charles Frankish, Jorge Mazza, William Moote, Piyush Patel, Helen Ramsdale, and William Yang. "Budesonide Aqueous Nasal Spray and Pressurized Metered Dose Inhaler in the Treatment of Adult Patients with Seasonal Allergic Rhinitis." American Journal of Rhinology 11, no. 1 (January 1997): 77–84. http://dx.doi.org/10.2500/105065897781446847.

Full text
Abstract:
Budesonide, a topical corticosteroid used in the treatment of seasonal allergic rhinitis, can be administered to the nose as an aerosol via a pressurized metered dose inhaler (pMDI) or as a metered nasal pump spray. Studies have shown that about 64% (256 μg) of a nominal dose of 400 μg budesonide pMDI preparation is delivered to the patient compared with 100% of the nominal dose of the pump spray. The present study was undertaken to assess the efficacy and safety of budesonide delivered via a nasal pMDI twice daily (Rhinocort® pMDI, at 400 μg/day) with an aqueous suspension of budesonide delivered via a metered nasal pump spray once daily (Rhinocort® Aqua, at 256 μg/day or 400 μg/day). The multicenter, double-blind, randomized, placebo-controlled, parallel-group study was conducted in 318 patients (154 men, 164 women; aged 12–67 years) with ragweed-induced seasonal allergic rhinitis. A 1-week baseline period was followed by a 3-week treatment. Nasal symptoms were recorded by the patients, adverse events were noted, an overall evaluation of treatment efficacy was made, and urine cortisol and creatinine levels were measured. Substantial or total control of symptoms was achieved in 83.8% of patients treated with 256 μg of aqueous budesonide, 76.3% with 400 μg of aqueous budesonide, and 80.8% with 400 μg of budesonide pMDI; these were all significantly different (p < 0.001) compared with placebo (23.4% of patients). There were no significant differences in the 24-hour urine cortisol levels between the groups and there were few, infrequent adverse events, similar between the groups and resolved completely on discontinuation of treatment. It was concluded that budesonide, given once daily as 256 μg or 400 μg in an aqueous suspension or twice daily as 400 μg in a pMDI provides good alleviation of the symptoms of seasonal allergic rhinitis with no significant risk of suppression of urine cortisol.
APA, Harvard, Vancouver, ISO, and other styles
9

Thomas, Brandon J., Mohammad Absar, Renishkumar Delvadia, Denise S. Conti, Kimberly Witzmann, and Changning Guo. "Analytical method development for characterizing ingredient-specific particle size distributions of nasal spray suspension products." Journal of Pharmaceutical Sciences 110, no. 7 (July 2021): 2778–88. http://dx.doi.org/10.1016/j.xphs.2021.03.005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Nakowitsch, Sabine, Christiane Koller, Jan-Marcus Seifert, Marielle König-Schuster, Nicole Unger-Manhart, Cornelia Siegl, Norman Kirchoff, et al. "Saponin Micelles Lead to High Mucosal Permeation and In Vivo Efficacy of Solubilized Budesonide." Pharmaceutics 12, no. 9 (September 5, 2020): 847. http://dx.doi.org/10.3390/pharmaceutics12090847.

Full text
Abstract:
Due to fast nasal mucociliary clearance, only the dissolved drug content can effectively permeate the mucosa and be pharmaceutically active after intranasal application of suspensions. Therefore, the aim of this study was to increase the budesonide concentration in solution of a nasal spray formulation. Budesonide, a highly water-insoluble corticosteroid, was successfully solubilized using a micellar formulation comprising escin, propylene glycol and dexpanthenol in an aqueous buffered environment (“Budesolv”). A formulation based on this micellar system was well-tolerated in the nasal cavity as shown in a good laboratory practice (GLP) local tolerance study in rabbits. Ex vivo permeation studies into porcine nasal mucosa revealed a faster and more efficient absorption. Budesolv with 300 µg/mL solubilized budesonide resulted in a budesonide concentration of 42 µg/g tissue after only 15 min incubation. In comparison, incubation with the marketed product Rhinocort® aqua 64 (1.28 mg/mL budesonide as suspension) led to 15 µg/g tissue. The in vivo tumor-necrosis-factor (TNF)-α secretion in an acute lung inflammation mouse model was significantly reduced (p < 0.001) following a prophylactic treatment with Budesolv compared to Rhinocort® aqua 64. Successful treatment 15 min after the challenge was only possible with Budesolv (40% reduction of TNF-α, p = 0.0012) suggesting a faster onset of action. The data reveal that solubilization based on saponin micelles presents an opportunity for the development of products containing hardly soluble substances that result in a faster onset and a better topical treatment effect.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Suspension nasal spray"

1

Azimi, Mandana. "EVALUATION OF THE REGIONAL DRUG DEPOSITION OF NASAL DELIVERY DEVICES USING IN VITRO REALISTIC NASAL MODELS." VCU Scholars Compass, 2017. http://scholarscompass.vcu.edu/etd/4780.

Full text
Abstract:
The overall objectives of this research project were i) to develop and evaluate methods of characterizing nasal spray products using realistic nasal airway models as more clinically relevant in vitro tools and ii) to develop and evaluate a novel high-efficiency antibiotic nanoparticle dry powder formulation and delivery device. Two physically realistic nasal airway models were used to assess the effects of patient-use experimental conditions, nasal airway geometry and formulation / device properties on the delivery efficiency of nasal spray products. There was a large variability in drug delivery to the middle passages ranging from 17 – 57 % and 47 – 77 % with respect to patient use conditions for the two nasal airway geometries. The patient use variables of nasal spray position, head angle and nasal inhalation timing with respect to spray actuation were found to be significant in determining nasal valve penetration and middle passage deposition of Nasonex®. The developed test methods were able to reproducibly generate similar nasal deposition profiles for nasal spray products with similar plume and droplet characteristics. Differences in spray plume geometry (smaller plume diameter resulted in higher middle passage drug delivery) were observed to have more influence on regional nasal drug deposition than changes to droplet size for mometasone furoate formulations in the realistic airway models. Ciprofloxacin nanoparticles with a mean (SD) volume diameter of 120 (10) nm suitable for penetration through mucus and biofilm layers were prepared using sonocrystallization technique. These ciprofloxacin nanoparticles were then spray dried in a PVP K30 matrix to form nanocomposite particles with a mean (SD) volume diameter of 5.6 (0.1) µm. High efficiency targeted delivery of the nanocomposite nasal powder formulation was achieved using a modified low flow VCU DPI in combination with a novel breathing maneuver; delivering 73 % of the delivered dose to the middle passages. A modified version of the nasal airway model accommodating Transwell® inserts and a Calu-3 monolayer was developed to allow realistic deposition and evaluation of the nasal powder. The nanocomposite formulation was observed to demonstrate improved dissolution and transepithelial transport (flux = 725 ng/h/cm2) compared to unprocessed ciprofloxacin powder (flux = 321 ng/h/cm2).
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Suspension nasal spray"

1

Arabzadeh, Sanaz, and Ali Dolatabadi. "Suspension Spray in a Twin-Fluid Atomizer." In ASME/JSME 2007 5th Joint Fluids Engineering Conference. ASMEDC, 2007. http://dx.doi.org/10.1115/fedsm2007-37284.

Full text
Abstract:
Atomization of suspension solutions has a wide range of applications in many industrial processes. The application ranges from spray drug products, such as nasal spray and inhalation solution to spray drying, plasma spraying and coatings. In any atomization process the main spray characteristics are defined as drop size and velocity distributions, the spray path and the distribution of the liquid throughout the spray. These distributions are affected by several parameters including liquid and gas physical properties, nozzle geometry and operating conditions [1]. Thus understanding the behavior of gas and liquid flow through the nozzle is crucial to predict the thickness and momentum of the liquid flow at the outlet of the atomizer. In this work the Multi-Fluid Marker and Cell (MFMAC) technique is used to numerically model the structure of internal two-phase flow inside an aerated-liquid jet. The behavior of liquid film in the discharge passage was investigated using different Gas to Liquid mass Ratio (GLR) and these numerical results were compared with the available experimental data. This work was done as a baseline to validate the simulations and the effect of suspension solid particles on the structure of the two-phase flow at the exit cross section of the nozzle was also studied. The effect of concentration of solid particles on the performance of the atomizer is considered through change in the liquid bulk density and viscosity. By increasing in the amount of aerating gas, the liquid film formed in the discharge orifice, becomes thinner and the gas/liquid velocity ratio and momentum flux at the nozzle exit increases. It was found that the variation of solid particle concentration can have an influence on the internal flow characteristics such as the liquid thickness and the flow pattern inside the nozzle discharge passage.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Suspension nasal spray' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography